StockGlow

Stoke Therapeutics, Inc. (STOK)

Develops genetic disease treatments using special molecules that turn up protein production in the body.

$28.87-0.02%Healthcare
Compare STOK with
StockGlow Score
64
Leaning Bullish
BearishBullish
1 year ago+123.6%

The outlook

STOK is trading below both its 50- and 200-day moving averages, sitting midway through its 52-week range. Analyst consensus is Strong Buy with an average price target about 59% above the current price. The overall sentiment leans bullish despite recent price weakness.

What’s behind the score

Analyst consensusStrong Buy — 1.1 avg of 11 analysts
Price trendBelow its 50- & 200-day averages
52-week range59% of the way from its 52-week low to high
Price targetAvg target +59% vs current price

Analyst price target

~12-month · 11 analysts
$45.82average target+58.7% vs now
Now $28.87
Low $35.00High $60.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$1.80B
52-wk high
$40.22
52-wk low
$12.25
50-day avg
$30.36
200-day avg
$31.67
Trailing P/E
—

Similar stocks

ALECAlector, Inc.$1.52+0.66%GOSSGossamer Bio, Inc.$0.20-1.76%PHATPhathom Pharmaceuticals, Inc.$11.65-2.51%SRRKScholar Rock Holding Corporation$48.44-1.00%FDMT4D Molecular Therapeutics, Inc.$9.79-5.73%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy